Fibrates and statins in the treatment of diabetic retinopathy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 396-405

  Ansquer, Jean Claude ^a   Crimet, Dominique ^a   Foucher, Christelle ^a  

^a Laboratoires Fournier SA   (France)

Author keywords

Clinical trials; Diabetic retinopathy; Fibrates; Statins

Indexed keywords

ANDROSTERONE; ATORVASTATIN; CLOFIBRATE; ETOFIBRATE; FENOFIBRATE; GLUCOSE; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; BLOOD GLUCOSE MONITORING; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPOPROTEINEMIA; HYPERTENSION; LASER COAGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; RISK FACTOR; VISUAL ACUITY;

BLINDNESS; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 79551655662     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480570     Document Type: Article

References (71)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
2. CDC National Health Interview Survey (NHIS). Early Release of Selected Estimates Based on Data from the January-September 2007. National Health Interview Survey, 2007.
3. Roglic, G.; Unwin, N.; Bennett, P.H.; Mathers, C.; Tuomilehto, J.; Nag, S.; Connolly, V.; King, H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care, 2005, 28(9), 2130-2135.
4. Fowler, M.J. Microvascular and macrovascular complications of diabetes. Clin. Diabetes, 2008, 26(2), 77-82.
5. Avogaro, A.; Giorda, C.; Maggini, M.; Mannucci, E.; Raschetti, R.; Lombardo, F.; Spila-Alegiani, S.; Turco, S.; Velussi, M.; Ferran-nini, E.; Diabetes and Informatics Study Group. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care, 2007, 30(5), 1241-1247.
6. Cheung, N.; Wang, J.J.; Klein, R.; Couper, D.J.; Sharrett, A.R.; Wong, T.Y. Diabetic retinopathy and the risk of coronary heart disease. The Atherosclerosis Risk in Communities Study. Diabetes Care, 2007a, 30(7), 1742-1746.
7. Cheung, N.; Rogers, S.; Couper, D.J.; Klein, R.; Sharrett, A.R.; Wong, T.Y. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke, 2007b, 38(2), 398-401.
8. Targher, G.; Bertolini, L.; Zenari, L.; Lippi, G.; Pichiri, I.; Zoppini, G.; Muggeo, M.; Arcaro, G. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet. Med., 2008, 25(1), 45-50.
9. Cheung, N.; Wang, J.J.; Rogers, S.L.; Brancati, F.; Klein, R.; Sharrett, A.R.; Wong, T.Y.; ARIC (Atherosclerosis Risk In Communities) Study Investigators. Diabetic retinopathy and risk of heart failure. J. Am. Coll. Cardiol., 2008, 51(16), 573-578.
10. Juutilainen, A.; Lehto, S.; Rönnemaa, T.; Pyörälä, K.; Laakso, M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care, 2007, 30(2), 292-299.
11. Prevention of blindness from Diabetes Mellitus. Report of a WHO consultation in Geneva, 9-11 November 2005. Switzerland: WHO Library Cataloguing-in-publication Data 2006.
12. Davidson, J.A.; Ciulla, T.A.; McGill, J.B.; Kles, K.A.; Anderson, P.W. How the diabetic eye loses vision. Endocrine, 2007, 32(1), 107-116.
13. Bearse, M.A.; Adams, A.J.; Han, Y.; Schneck, M.E.; Bronson-Castain, K.; Barez, S. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog. Retin. Eye Res., 2006, 25(5), 425-448.
14. Frank, R.N. Diabetic retinopathy. N. Engl. J. Med., 2004, 350(1), 48-58.
15. The Diabetes Control and Complication Trial Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes, 1996, 45(10), 1289-1298.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131), 837-853.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352(9131), 854-865.
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317(7160), 703-713.
19. The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2560-2572.
20. Matthews, D.R.; Stratton, I.M.; Aldington, S.J.; Holman, R.R.; Kohner, E.M. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch. Oph-thalmol., 2004, 122(11), 1631-1640.
21. Van Hecke, M.V.; Dekker, J.M.; Nijpels, G.; Teerlink, T.; Jakobs, C.; Stolk, R.P.; Heine, R.J.; Bouter, L.M.; Polak, B.C.; Stehouwer, C.D. Homocysteine, S-adenosylmethionine and S-adenosylhomo-cysteine are associated with retinal microvascular abnormalities: the Hoorn Study. Clin. Sci. (Lond)., 2008, 114(7), 479-487.
22. Fosmark, D.A.; Torjesen, P.A.; Kilhovd, B.K.; Berg, T.J.; Sandvik, L.; Hanssen, K.F.; Agardh, C.D.; Agardh, E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism, 2006, 55(2), 232-236.
23. The Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes. Diabetes Care, 2006, 29(12), 2701-2707.
24. Olsen, B.S.; Sjølie, A.K.; Hougaard, P.; Johannesen, J.; Marinelli, K.; Jacobsen, B.B.; Mortensen, H.B. Danish Study Group of Diabetes in Childhood. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J. Diabetes Complications, 2004, 18(3), 160-164.
25. Monti, M.C.; Lonsdale, J.T.; Montomoli, C.; Montross, R.; Schlag, E.; Greenberg, D.A. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of american families with type 1 diabetes. J. Clin. Endocrinol. Metab., 2007, 92(12), 4650-4655.
26. Fava, S.; Hattersley, A.T. The role of genetic susceptibility in diabetic nephropathy: evidence from family studies. Nephrol. Dial. Transplant., 2002, 17(9), 1543-1546.
27. Tong, Z.; Yang, Z.; Patel, S.; Chen, H.; Gibbs, D.; Yang, X.; Hau, V.S.; Kaminoh, Y.; Harmon, J.; Pearson, E.; Buehler, J.; Chen, Y.; Yu, B.; Tinkham, N.H.; Zabriskie, N.A.; Zeng, J.; Luo, L.; Sun, J.K.; Prakash, M.; Hamam, R.N.; Tonna, S.; Constantine, R.; Ron-quillo, C.C.; Sadda, S.; Avery, R.L.; Brand, J.M.; London, N.; An-duze, A.L.; King, G.L.; Bernstein, P.S.; Watkins, S.; Genetics of Diabetes and Diabetic Complication Study Group, Jorde, L.B.; Li, D.Y.; Aiello, L.P.; Pollak, M.R.; Zhang, K. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl. Acad. Sci. USA, 2008, 105(19), 6998-7003.
28. Jenkins, A.J.; Rowley, K.G.; Lyons, T.J.; Best, J.D.; Hill, M.A.; Klein, R.L. Lipoproteins and diabetic microvascular complications. Curr. Pharm. Design, 2004, 10(27), 3395-3418.
29. Porta, M.; Sjoelie, A.K.; Chaturvedi, N.; Stevens, L.; Rottiers, R.; Veglio, M.; Fuller, J.H.; EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia, 2001, 44(12), 2203-2209.
30. Ferris, F.L.; Chew, E.Y.; Hoogwerf, B.J. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care, 1996, 19(11), 1291-1293.
31. Chew, E.Y.; Klein, M.L.; Ferris, F.L.; Remaley, N.A.; Murphy, R.P.; Chantry, K.; Hoogwerf, B.J.; Miller, D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS Report 22. Arch. Ophthalmol, 1996, 114(9), 1079-1084.
32. Ucgun, N.I.; Yildirim, Z.; Kilic, N.; Gursel, E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann. NY Acad. Sci., 2007, 1100, 213-217.
33. Davis, M.D.; Fisher, M.R.; Gangnon, R.E.; Barton, F.; Aiello, L.M.; Chew, E.Y.; Ferris, III F.L.; Knatterud, G.L.; For the Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Early Treatment Diabetic Retinopathy Study Report 18. Invest. Ophthalmol. Vis. Sci., 1998, 39(2), 233-252.
34. Orchard, T.J.; Dorman, J.S.; Maser, R.E.; Becker, D.J.; Ellis, D.; LaPorte, R.E.; Kuller, L.H.; Wolfson, S.K. Jr; Drash, A.L. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care, 1990, 13(7), 741-747.
35. Lyons, T.J.; Jenkins, A.J.; Zheng, D.; Lackland, D.T.; McGee, D.; Garvey, W.T.; Klein, R.L. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol. Vis. Sci., 2004, 45(3), 910-918.
36. Turczyhski, B.; Michalska-Malecka, K.; Slowihska, L.; Szczesny, S.; Romaniuk, W. Correlations between the severity of retinopathy in diabetic patients and whole blood and plasma viscosity. Clin. Hemorheol. Microcirc, 2003, 29(2), 129-137.
37. Fujisawa, T.; Ikegami, H.; Yamato, E.; Kawaguchi, Y.; Ueda, H.; Shintani, M.; Nojima, K.; Kawabata, Y.; Ono, M.; Nishino, T.; Noso, S.; Yamada, K.; Babaya, N.; Okamoto, N.; Ohguro, N.; Fukuda, M.; Ogihara, T. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. Diabet. Med., 1999, 16(6), 522-526.
38. Duncan, L.J.; Cullen, J.F.; Ireland, J.T.; Nolan, J.; Clarke, B.F.; Oliver, M.F. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes, 1968, 17(7), 458-467.
39. Harrold, B.P.; Marmion, V.J.; Gough, K.R. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes, 1969, 18(5), 285-291.
40. Cullen, J.F.; Town, S.M.; Campbell, C.J. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans. Ophthalmol. Soc. U.K, 1994, 94(2), 554-562.
41. Dorne, P. A. Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years. Arch. Ophtalmol, (Paris), 1977, 37(5), 393-400. [Article in French].
42. Freyberger, H.; Schifferdecker, E.; Schatz, H. Regression of hard exudates in diabetic background retinopathy in therapy with etofi-brate antilipemic agent. Med. Klin., 1994, 89(11), 594-597. [Article in German].
43. Emmerich, K.H.; Poritis, N.; Stelmane, I.; Klindzane, M.; Erbler H.; Goldsteine, J.; Goertelmeyer, R. Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy. Klin. Monatblatter Augenheilkunde, 2009, 226(7), 561-567.
44. Havel, E.; Rencova, J.; Novak, L.; Blaha, V.; Solichova, D.; Bra-tova, M.; Zadak, Z. Serum lipoproteins lowering and diabetic exudative retinopathy. Atherosclerosis, 1997, 134(1-2), 309.
45. FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc. Diabetol., 2004, 3, 9.
46. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (The FIELD study): randomised controlled trial. Lancet, 2005, 366(9500), 1849-1861.
47. Keech, A.C.; Mitchell, P.; Summanen, P.A.; O'Day, J.O.; Davis, T.M.E.; Moffitt, M.S.; Taskinen, M.R.; Simes, R.J.; Tse, D.; Williamson, E.; Merrifield, A.; Laatikainen, L.T.; d'Emden, M.C.; Crimet, D.C.; O'Connell, R.L.; Colman, P.G.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, 2007, 370(9600), 1687-1697.
48. Gordon, B.; Chang, S.; Kavanagh, M.; Berrocal, M.; Yannuzzi, L.; Robertson, C.; Drexler, A. The effects of lipid lowering on diabetic retinopathy. Am. J. Ophthalmol., 1991, 112(4), 385-391.
49. Seguchi, H.; Nishikawa, N.; Hiroshi, I.; Kawaguchi, S.; Tanaka, M.; Tanaka, Y.; Hosoi, C. Effect of simvastatin on diabetic reti-nopathy with hard exudate. Folia Ophthalmol. Jpn., 1996, 47(12), 1485-1490.
50. Takaba, T.; Nishikawa, N.; Mikajiri, K.; Fukui, T.; Tsukamoto, Y.; Kawasaki, Y.; Tanaka, Y.; Kosugi, K. Effect of atorvastatin on diabetic retinopathy with hard exudate. Folia Ophthalmol. Jpn., 2006, 57(4), 295-300.
51. Sen, K.; Misra, A.; Kumar, A.; Pandey, R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholes-terolemia. Diabetes Res. Clin. Pract., 2002, 56(1), 1-11.
52. Gupta, A.; Gupta, V.; Thapar, S.; Bhansali, A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol., 2004, 137(4), 675-682.
53. Banerjee, S.; Denniston, A.K.O.; Gibson, J.M.; Dodson, P.M. Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? Eye, 2004, 18(8), 821-825.
54. Zhang, J.; McGwin, G. Association of statin use with the risk of developing diabetic retinopathy. Arch. Ophthalmol., 2007, 125(8), 1096-1099.
55. Collins, R.; Armitage, J.; Parish, S.; Sleigh, P.; Peto, R. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet, 2003, 361(9374), 2005-2016.
56. Colhoun, H.M.; Betteridge, D.J.; Hitman, G.A.; Neil, A.W.; Livingstone, S.J.; Thomasson, M.J.; Mackess, M.I.; Charlton-Menys, V.; Fuller, J.H.; on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet, 2004, 364(9435), 685-696.
57. Dodson, P.M. Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Pract. Diab. Int., 2008, 25(2), 76-79.
58. Antonetti, D.A.; Barber, A.J.; Bronson, S.K.; Freeman, W.M.; Gardner, T.W.; Jefferson, L.S.; Kester, M.; Kimball, S.R.; Krady, J.K.; LaNoue, K.F.; Norbury, C.C.; Quinn, P.G.; Sandirasegarane, L.; Simpson, I.A. JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy. Seeing beyond glucose-induced microvascular disease. Diabetes, 2006, 55(9), 2401-2411.
59. Ansquer, J.C.; Foucher, C; Aubonnet, P.; Le Malicot, K. Fibrates and microvascular complications in diabetes - insight from the field study. Curr. Pharm. Des., 2009, 15(5), 537-552.
60. Aiello, L.P.; Bursell, S.E.; Clermont, A.; Duh, E.; Ishii, H.; Takagi, C; Mori, F.; Ciulla, T. A.; Ways, K.; Jirousek, M.; Smith, L.E.; King, G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by oral effective beta-isoform-selective inhibitor. Diabetes, 1997, 46(9), 1473-1480.
61. Mysiorek, C; Culot, M.; Dehouck, L.; Derudas, B.; Staels, B.; Bordet, R.; Cecchelli, R.; Fenart, L.; Berezowski, V. Peroxisome proliferator-activated receptor a activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyper-permeability in the blood-brain barrier. Curr. Neurovasc. Res., 2009, 6(3), 181-193.
62. Villarroel, M.; Garcia-Ramirez, M.; Corraliza, L.; Hernandez, C; Simo, R. Fenofibrate restores the barrier function of human retinal pigment epithelial cells cultured under conditions mimicking the diabetic milieu. Diabetologia, 2009, 52(Suppl. 1), S346.
63. Li, J.; Wang, J.J.; Chen, D.; Mott, R.; Yu, Q.; Ma, J.X.; Zhang, S.X. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp. Eye Res., 2009, 89(1), 71-78.
64. Itoh, Y.; Kimoto, K.; Imaizumi, M.; Nakatsuka, K. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Exp. Eye Res., 2007, 84(3), 464-472.
65. Van Thiel, G.C.; Huisman, R.H.; Moshage, H.; Yap, S.H.; Cohen, L.H. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta, 1995, 1254(1), 105-111.
66. Capeáns, C; Piñeiro, A.; Pardo, M.; Carneiro, C; Blanco, M.J.; Viñuela, J.M.; Sánchez Salorio, M.; Domínguez, F. Role of inhibitors of isoprenylation in proliferation, phenotype and apoptosis of human retinal pigment epithelium. Graefes. Arch. Clin. Exp. Ophtalmol, 2001, 239(3), 188-198.
67. Kim, J.; Ahn, J.H.; Kim, J.H.; Yu, Y.S.; Kim, H.S.; Ha, J.; Shinn, S.H.; Oh, Y.S. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp. Eye Res., 2007, 84(5), 886-893.
68. Zamora, D.O.; Riviere, M.; Choi, D.; Pan, Y.; Planck, S.R.; Rosenbaum, J.T.; David, L.L.; Smith, J.R. Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin. Mol. Vis., 2007, 13, 2058-2065.
69. The ACCORD Study Group and ACCORD eye study group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med., [online] 2010 June 29.2010 at NEJM.org.
70. Sander, B.; Nellemann Thornit, D.; Colmorn, L.; Strøm, C; Girach, A.; Hubbard, L.D.; Lund-Andersen, H.; Larsen, M. Progression of diabetic macular edema: correlation with blood-retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest. Ophthalmol. Vis. Sci., 2007, 48(9), 3983-3987.
71. Effect of choline fenofibrate (SLV348) on macular edema Clinical trials. Gov identifier NCT00683176 Clinical Trials.Gov Accessed. January, 20 2010.